Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
AstraZeneca
Mallinckrodt
Harvard Business School
Merck

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,540,665

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,540,665 protect, and when does it expire?

Patent 8,540,665 protects ZINGO and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 8,540,665
Title:Particle cassettes and processes therefor
Abstract: An article for use in manufacturing particle cassettes comprising one or more single pieces of membrane having a plurality of gas flow passages bonded thereto. The article allows convenient manufacture of particle cassettes. Two such articles may be employed to provide a finished particle cassette and a production line in which a plurality of gas flow passages are conveyed on a single membrane is disclosed.
Inventor(s): Bates; Nigel Robert (The Oxford Science Park, GB), Price; Philip Thomas (The Oxford Science Park, GB)
Assignee: Powder Pharmaceuticals Inc. (Hong Kong, HK)
Application Number:12/612,586
Patent Claim Types:
see list of patent claims
Device; Use;

Drugs Protected by US Patent 8,540,665

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Powder Pharms ZINGO lidocaine hydrochloride SYSTEM;INTRADERMAL 022114-001 Aug 16, 2007 RX No No   Start Trial   Start Trial ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,540,665

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0708758May 04, 2007

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKesson
Merck
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.